Clinical Trials Browser

tremelimumab × Thoracic × Clear all

NCT07288034 2026-04-15

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02888743 2026-04-13

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

Phase 2 Active not recruiting

110 enrolled 21 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT03923270 2026-04-01

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Phase 1 Active not recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06008093 2026-03-30

TRITON

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04499053 2026-03-16

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03164616 2026-03-13

POSEIDON

Phase 3 Active not recruiting

1,186 enrolled 26 charts 2 FDA

Non Small Cell Lung Cancer NSCLC

NCT07391670 2026-03-12

IMFINZI-subQ

Phase 1 Not yet recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma

NCT01843374 2026-03-05

Tremelimumab

Phase 2 Active not recruiting

571 enrolled 19 charts

Other solid neoplasmThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Mesothelioma, Malignant

NCT03057106 2026-03-03

Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

Phase 2 Active not recruiting

301 enrolled 15 charts

Lung Cancer Metastatic

NCT02453282 2026-03-02

MYSTIC

Phase 3 Active not recruiting

1,118 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT03965468 2026-02-09

CHESS

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03075527 2026-01-08

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

Phase 2 Terminated

19 enrolled 12 charts

Other solid neoplasmThoracic

Mesothelioma

NCT05380713 2025-12-29

......SMARTEST Trial......

Phase 2 Completed

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT02639026 2025-11-25

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Phase 1 Completed

BreastDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT03703297 2025-11-21

ADRIATIC

Phase 3 Active not recruiting

730 enrolled 19 charts 3 FDA

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT03581487 2025-11-05

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03043872 2025-10-21

CASPIAN

Phase 3 Active not recruiting

987 enrolled 42 charts 3 FDA

Small Cell Lung Carcinoma

NCT03237377 2025-10-14

Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

Phase 2 Terminated

9 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT05932199 2025-09-25

Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Phase 1/2 Recruiting

Other solid neoplasmThoracic

Mesothelioma

NCT03212469 2025-05-08

ABIMMUNE

Phase 1/2 Completed

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Neoplasms, Lung Neoplasms

NCT04585490 2025-05-06

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03509012 2025-01-14

CLOVER

Phase 1 Completed

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT04287894 2024-11-06

Induction

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT03693612 2024-08-28

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

Phase 1/2 Completed

26 enrolled 47 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms

NCT02352948 2024-07-26

ARCTIC

Phase 3 Completed

597 enrolled 23 charts

Non - Small Cell Lung Cancer NSCLC

NCT02937818 2024-06-07

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Phase 2 Completed

72 enrolled 29 charts

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

NCT03022500 2024-05-29

Pulmonary sarcomatoid_MEDI4736+Treme

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT03963414 2023-08-28

A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

Phase 1 Terminated

Small Cell Lung Carcinoma

NCT04625699 2023-06-06

Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT03275597 2023-05-15

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT03994393 2023-04-21

ILLUMINATE

Phase 2 Unknown

EGFR Mutant Advanced Non Small Cell Lung Cancer

NCT03975114 2023-03-24

MILES-5

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

DermatologicGenitourinaryThoracic

Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT03164772 2022-10-10

Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC

Phase 1/2 Completed

61 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT02592551 2022-09-29

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

Phase 2 Completed

24 enrolled 22 charts

Other solid neoplasmThoracic

Mesothelioma

NCT03319316 2022-01-10

SOLUTION

Phase 2 Withdrawn

Squamous Non-small Cell Lung Cancer

NCT02701400 2021-06-22

Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer

Phase 2 Completed

18 enrolled 13 charts

Small Cell Lung Carcinoma

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Phase 1 Completed

BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Phase 1 Completed

BreastDermatologicGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

NCT02000947 2019-10-31

D4190C00006

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02179671 2019-08-02

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Phase 2 Completed

32 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02141347 2018-12-12

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

Phase 1 Completed

Other solid neoplasmThoracic

Part A and B: Advanced Solid Malignancies

NCT03085849 2018-12-10

SGI-110 Plus Durvalumab/Tremelimumab in SCLC

Phase 1 Completed

Small Cell Lung Carcinoma

NCT03130764 2017-12-06

Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02040064 2016-06-09

GEFTREM

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT02588131 2015-10-27

A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)

Phase 2 Unknown

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT01655888 2012-08-02

The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma

Phase 2 Unknown

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT01649024 2012-07-25

A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma

Phase 2 Unknown

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT00312975 2012-06-07

Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung